Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01762839 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Cardiac Safety of Oritavancin in Healthy Participants
A Phase 1 study, sponsored by Melinta Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
NCT01762839: Completed Phase 1 study, sponsored by Melinta Therapeutics.
NCT01762839 is a Phase 1 study that has completed, run by Melinta Therapeutics. The registered enrollment target is 150 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (150% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01762839, a Phase 1 study, has completed, sponsored by Melinta Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
Study Summary
The purpose of the study was to generate cardiac safety data using a supratherapeutic oritavancin dose of 1600 milligrams (mg).
Primary Outcome
Placebo-adjusted change from baseline in QTcF (QTc with the Fridericia correction) between each treatment and placebo.
Interventions
- DRUG Placebo
- DRUG Moxifloxacin
- DRUG Single-Dose IV Oritavancin Diphosphate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2012-12-27 |
| Est. Completion | 2013-02-11 |
| Phase | Phase 1 |
What the finished NCT01762839 record still lists
NCT01762839 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (150% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01762839 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01762839 about?
NCT01762839 is a clinical study titled "A Study to Assess the Cardiac Safety of Oritavancin in Healthy Participants". The purpose of the study was to generate cardiac safety data using a supratherapeutic oritavancin dose of 1600 milligrams (mg).
What is the current status of trial NCT01762839?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2012-12-27. Estimated completion is 2013-02-11.
What interventions are being tested in trial NCT01762839?
The interventions under investigation include: Placebo (DRUG), Moxifloxacin (DRUG), Single-Dose IV Oritavancin Diphosphate (DRUG).
Who is sponsoring clinical trial NCT01762839?
This trial is sponsored by Melinta Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01762839's enrollment target sits among peer trials
150 363rd of 2000 higher than 1,620 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI